Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics".

Organisations Organisation Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
  Group Calliditas Therapeutics (Group)
  Organisation 2 Optimum Strategic Communications
Products Product Nefecon®
  Product 2 public relations / investor relations / marcom (services)
Index term Index term Calliditas Therapeutics–Optimum Strategic Communications: public relations, 201711 service existent by Optimum
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Widell, Mikael (Pharmalink AB 201708– Head of Communications before Cord Communications + Nordic Capital)

The specialty pharmaceutical company Pharmalink AB today announced that it has changed its name to Calliditas Therapeutics AB (“Calliditas Therapeutics” or the “company”).

The Swedish Companies Registration Office has approved and registered the company's change of name from Pharmalink AB to Calliditas Therapeutics AB. More information about Calliditas Therapeutics and its clinical projects can be found on the new website

For further information, please contact:

Calliditas Therapeutics AB
Renée Aguiar-Lucander, Chief Executive Officer
Mobile: +46 (0)72 252 1006

Mikael Widell, Head of Communications
Mobile: +46 (0)70 311 9960

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0)203 714 1787

Notes to editors

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs.

Visit for further information.

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm

Company number: 556659-9766

Record changed: 2017-11-26


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Calliditas Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top